Insights

Solid-State Analytics: The Subcontracted Blind Spot in CDMO Sourcing

When generalist CDMOs quietly outsource polymorph and crystal form work, you lose visibility, speed, and accountability.

21 October 2026 7 min read PCL Research & Manufacturing
Solid-State Analytics: The Subcontracted Blind Spot in CDMO Sourcing

If you’ve ever asked your CDMO exactly who runs your XRPD and solid-state NMR work and received a vague answer or a referral to an unnamed ‘partner lab,’ you have already found a gap in your sourcing strategy. Solid-state analytics — the discipline that determines whether your API will remain stable, bioavailable, and patentable — quietly becomes somebody else’s problem, run under somebody else’s quality system.

The Quiet Practice Nobody Puts in the Proposal

Full-service CDMOs market integrated CMC packages: synthesis, formulation, analytical development, stability, and release testing, all under one roof. In practice, solid-state characterization is frequently the one workstream that is not actually performed in-house. It is routed, often without prominent disclosure, to a third-party laboratory that specializes in crystal engineering.

This is not a scandal — it is a structural consequence of how generalist CDMOs built their capabilities. Synthesis, scale-up, and conventional analytical chemistry scaled well across many sites over the past two decades. Solid-state science, by contrast, requires a narrower, deeply specialized skill set that most generalist organizations never built internally, and few have chosen to.

The result is a sourcing blind spot. Clients sign a single contract believing they are buying integrated expertise, when in reality a critical piece of their drug substance characterization sits one or two vendor layers removed from the entity they are actually paying.

Why Solid-State Analytics Is Not a Commodity Service

Running an XRPD scan is straightforward. Interpreting it correctly is not. Distinguishing a genuine polymorphic transition from preferred orientation artifacts, discriminating a stoichiometric hydrate from a channel solvate, or recognizing partial amorphization hidden beneath a crystalline halo requires pattern-recognition built on years of dedicated practice, not a standard operating procedure read off a shelf.

The same applies across the full toolkit: DSC and TGA data must be read together to separate a true polymorphic transition from simple decomposition or dehydration. Solid-state NMR is often the only technique sensitive enough to detect low-level amorphous content in an otherwise crystalline matrix. Raman spectroscopy, used in-situ, can track form conversion during crystallization in real time, but only if the spectral library behind it was built with rigor.

This is crystal engineering, not routine analytical chemistry. We say this as a company whose core competency — not a secondary service line — grew out of an academic research group dedicated specifically to solid-state science. The distinction matters because it shapes how a laboratory is staffed, how data is interpreted, and how defensible that interpretation is in front of a regulatory reviewer.

What Gets Lost in the Subcontracting Chain

Every additional layer between you and the scientist actually generating your data introduces friction, and friction compounds across a development program.

The most common consequences we see described by clients who have lived through this arrangement include:

The Strongest Counter-Argument — and Why It Doesn’t Hold

The honest counter-argument deserves a fair hearing: a single contract and a single invoice genuinely reduce vendor management overhead, which matters enormously to a lean biotech team running a small program with limited headcount. We do not dismiss that convenience; it is real, and for some organizations it is the deciding factor in a sourcing decision.

But convenience and integration are not the same thing. A single invoice that covers a hidden multi-site supply chain does not remove the underlying complexity — it only removes your visibility into it. You are still exposed to a subcontractor’s capacity constraints, queue priorities, and quality system, you simply no longer have a direct line of sight or contractual leverage over them.

Genuine integration means one site, one quality system, and one scientific team following your molecule from early screening through GMP release. A unified invoice that masks a fragmented delivery chain is administrative convenience dressed up as technical integration, and the difference becomes very visible the moment something goes wrong.

Beyond HPAPIs: The Same Logic Applies to Every Small Molecule Program

This issue is often framed as a high-potency compound problem, but the exposure is far broader. A standard small molecule NCE, a 505(b)(2) reformulation, or a generic line extension all carry real polymorphic risk that has nothing to do with containment classification.

Late-stage discovery of an unanticipated polymorph has delayed commercial launches, triggered costly reformulation, and in several well-documented industry cases, forced withdrawal and reformulation of marketed products. Co-crystal and salt form selection decisions made early in development also underpin patent strategy — a defensible, well-characterized solid form can be a genuine IP asset, while a poorly substantiated one can become a vulnerability during litigation.

Whether your program involves an OEB5 oncology payload or a conventional oral solid dose candidate, the fundamental question is identical: is the party generating your solid-state data the party with the deepest expertise in generating it, or the party that happened to win the overall CMC contract?

A Sourcing Framework: Questions to Ask Before You Sign

We recommend that procurement and R&D teams treat solid-state analytics as its own sourcing decision, evaluated on its own merits, even within a broader CDMO negotiation. A few direct questions tend to surface the answer quickly:

The Case for Direct Specialist Partnership

We built our organization around the opposite model. At PCL Research & Manufacturing, solid-state characterization and polymorph, salt, and co-crystal screening are not a subcontracted add-on to a broader CMC package — they are the core scientific competency the company was founded on, originating from a University of Bologna crystal engineering research group.

That continuity matters in practice. The same scientific team that runs early-stage polymorph screening and stability studies also supports GMP-compliant method validation and release testing, inside FDA-inspected, AIFA GMP-certified facilities with dedicated capability up to OEB5 containment and authorization for controlled substance research and manufacturing. There is no handoff, no second invoice, no second quality system to reconcile.

For sponsors, this translates into a shorter, more legible chain of accountability: one laboratory, one data trail, one team that already knows your molecule by the time it reaches GMP testing.

Solid-state analytics decides more about a drug substance’s future than its place on a project Gantt chart suggests — stability, bioavailability, patentability, and regulatory defensibility all trace back to it. If you are currently unsure who actually generates this data for your program, or whether that party has the specialist depth the work demands, we would welcome a conversation about what a direct, integrated partnership could look like for your next solid form or high-potency project.

Share

More insights

All articles